Mani Mohindru Buys 24,703 Shares of Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) CEO Mani Mohindru bought 24,703 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were acquired at an average price of $1.21 per share, with a total value of $29,890.63. Following the completion of the transaction, the chief executive officer owned 24,703 shares of the company’s stock, valued at approximately $29,890.63. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cardiff Oncology Trading Down 3.1%

NASDAQ CRDF opened at $1.26 on Wednesday. The stock has a market cap of $86.15 million, a PE ratio of -1.88 and a beta of 1.36. Cardiff Oncology, Inc. has a 12 month low of $1.16 and a 12 month high of $4.55. The company’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.96.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. As a group, sell-side analysts forecast that Cardiff Oncology, Inc. will post -0.66 earnings per share for the current year.

Institutional Trading of Cardiff Oncology

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in Cardiff Oncology during the 1st quarter valued at $164,000. Sei Investments Co. purchased a new stake in shares of Cardiff Oncology during the 1st quarter worth $89,000. Raymond James Financial Inc. boosted its position in Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after purchasing an additional 9,740 shares in the last quarter. Brooklyn Investment Group bought a new stake in Cardiff Oncology during the third quarter valued at about $26,000. Finally, Engineers Gate Manager LP purchased a new position in Cardiff Oncology in the second quarter valued at about $43,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Piper Sandler reduced their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Monday, May 18th. TD Cowen lowered Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright downgraded Cardiff Oncology from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Finally, Craig Hallum lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cardiff Oncology presently has an average rating of “Hold” and a consensus target price of $9.80.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.